rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I

Journal of Nuclear Medicine

Volumn 44, Issue 7, 2003, Pages 1065-1068

  Menzel, Christian ^a   Kranert, Wolfgang T ^a   Döbert, Natascha ^a   Diehl, Michaela ^a   Fietz, Thomas ^a   Hamscho, Nadja ^a   Berner, Uwe ^a   Grünwald, Frank ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Effective half life; Radioiodine; rhTSH; Thyroid cancer

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROXINE; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN;

ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG WITHDRAWAL; HEADACHE; HORMONAL REGULATION; HUMAN; HYPOTHYROIDISM; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; WHOLE BODY RADIATION; ADJUVANT CHEMOTHERAPY; AGE; BLOOD; EVALUATION; FEMALE; HALF LIFE TIME; MALE; METHODOLOGY; MIDDLE AGED; RADIATION DOSE; RADIOMETRY; RETROSPECTIVE STUDY; THYROID TUMOR; WHOLE BODY COUNTING;

AGE FACTORS; CHEMOTHERAPY, ADJUVANT; FEMALE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOMETRY; RADIOTHERAPY DOSAGE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN; WHOLE-BODY COUNTING;

EID: 0042388346     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:619-625.
2. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002;12:37-42.
3. 18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002;29:641-647.
4. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest. 2002;25:44-52.
5. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Memb. 1994;78:188-196.
6. Park S-G, Reynolds JC, Brucker-Davis, F, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidism [abstract]. J Nucl Med. 1996;37(suppl):15P.
7. Annals of the ICRP: Radiation Dose to Patients from Radiopharmaceuticals. Vol 53. New York, NY: Pergamon Press; 1993:259-278.
8. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2000;85:3640-3645.
9. Lippi F, Capezzone M, Angelini F, et al Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol. 2001;144:5-11.
10. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001; 11:865-869.